Literature DB >> 20096316

A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells.

Tao Zhao1, Hiroshi Harada, Yuji Teramura, Shotaro Tanaka, Satoshi Itasaka, Akiyo Morinibu, Kazumi Shinomiya, Yuxi Zhu, Hirofumi Hanaoka, Hiroo Iwata, Hideo Saji, Masahiro Hiraoka.   

Abstract

Matrix metalloproteinases (MMPs) are endopeptidases responsible for degrading the extracellular matrix (ECM) and remodeling tissue in both physiological and pathological processes. MMP2 and membrane-type 1 MMP (MT1-MMP) have been associated with tumor invasion, metastasis and angiogenesis; therefore, a molecular imaging strategy assessing their activity may help to predict the malignancy of tumors. Here, we established a novel method of specifically tagging the surface of MMP2- and MT1-MMP-positive cells, and applied it to the development of an optical imaging probe. We constructed a protein-based probe composed of a glutathione-S-transferase (GST)-tag (Inhibitory [I]-domain), a polypeptide as a specific substrate for both MMP2 and MT1-MMP (Cleaved [C]-domain), a transmembrane domain of the epidermal growth factor receptor (Transmembrane [TM]-domain), and DsRed2 (Fluorescent [F]-domain). In vitro experiments clearly demonstrated that, after the probe was cleaved at the C-domain by the MMPs, the resultant TM-F-domain was inserted into the cellular membrane. Optical imaging experiments in vivo demonstrated that the probe was cleaved and specifically remained in tumor xenografts in a MMP-dependent manner. These results indicate that the release of the I-C-domain through the proteolytic cleavage of the C-domain by MMP2 and MT1-MMP triggers the tagging of cellular membranes with the TM-F-domain. The present feasibility study opens the door to the development of a novel imaging probe for tumor malignancy using positron emission tomography as well as an optical imaging device. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096316     DOI: 10.1016/j.jconrel.2010.01.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

Review 1.  Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Authors:  Ayesha Khalid; Joy Wolfram; Ilaria Ferrari; Chaofeng Mu; Junhua Mai; Zhizhou Yang; Yuliang Zhao; Mauro Ferrari; Xiaojing Ma; Haifa Shen
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

2.  High-affinity peptide against MT1-MMP for in vivo tumor imaging.

Authors:  Lei Zhu; Huiling Wang; Lin Wang; Ye Wang; Kun Jiang; Cheng Li; Qingjie Ma; Shi Gao; Liping Wang; Wei Li; Mingjun Cai; Hongda Wang; Gang Niu; Seulki Lee; Wei Yang; Xuexun Fang; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-02-02       Impact factor: 9.776

3.  Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Authors:  Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; John N Freskos; Michael A Brown; Amolkumar S Karwa; Arati D Naik; Carol P Howard; Carolyn J Sympson; Alex Y Strongin
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

4.  Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases.

Authors:  Muthulekha Swamydas; Krista Ricci; Stephen L Rego; Didier Dréau
Journal:  Cell Adh Migr       Date:  2013-05-24       Impact factor: 3.405

5.  In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.

Authors:  Yoichi Shimizu; Takashi Temma; Isao Hara; Akira Makino; Naoya Kondo; Ei-Ichi Ozeki; Masahiro Ono; Hideo Saji
Journal:  Cancer Sci       Date:  2014-07-31       Impact factor: 6.716

6.  SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization.

Authors:  Tatsuya Suwa; Minoru Kobayashi; Yukari Shirai; Jin-Min Nam; Yoshiaki Tabuchi; Norihiko Takeda; Shusuke Akamatsu; Osamu Ogawa; Takashi Mizowaki; Ester M Hammond; Hiroshi Harada
Journal:  JCI Insight       Date:  2021-11-08

Review 7.  Imaging aspects of the tumor stroma with therapeutic implications.

Authors:  Lian Narunsky; Roni Oren; Filip Bochner; Michal Neeman
Journal:  Pharmacol Ther       Date:  2013-10-14       Impact factor: 12.310

8.  Investigation of a MMP-2 activity-dependent anchoring probe for nuclear imaging of cancer.

Authors:  Takashi Temma; Hirofumi Hanaoka; Aki Yonezawa; Naoya Kondo; Kohei Sano; Takeharu Sakamoto; Motoharu Seiki; Masahiro Ono; Hideo Saji
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.